Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study intends to evaluate how safe and well tolerated the LY2405319 compound is when given to people for 7 days (in Part 1) and 28 days (in Part 2). This study intends to also determine if there is a positive effect on lowering the level of glucose in people with type 2 diabetes.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Men and women without child bearing capability

• Ages 35 to 70 years

• Type 2 diabetic subjects, diagnosed for at least 3 months

• Average body weight (relative to height)

• Willing to be available for the duration of the study

Exclusion Criteria:

• Significant medical illnesses (except Type 2 diabetes)

• Abnormal 12-lead electrocardiogram (ECG )

• Current or previous use of insulin for greater than 7 days for control of diabetes

• Regular use of drugs of abuse

• Excessive alcohol use